- Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial2021 | First Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Dendritic Cell-Based Immunotherapy Induces Transient Clinical Response in Advanced Rat Fibrosarcoma - Comparison with Preventive Anti-tumour Vaccination2009 | Second Faculty of Medicine
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer2015 | Second Faculty of Medicine
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial2022 | Second Faculty of Medicine, First Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial2022 | Faculty of Medicine in Hradec Králové
- Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype2020 | Second Faculty of Medicine, First Faculty of Medicine
- Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines2016 | Second Faculty of Medicine